HondaY, TakahashiS, ZhangY, et al.: Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. J Gastroenterol Hepatol, 2015; 30:619–627.
2.
LiuQ, TaoYH, BaiRZ, ChangSJ, HuaD: Zoledronic acid inhibits growth of hepatocellular carcinoma cells in vitro and in vivo. Chin Med J (Engl), 2013; 126:1486–1490.
3.
MurthyS, TongH, HohlRJ: Regulation of fatty acid synthesis by farnesyl pyrophosphate. J Biol Chem, 2005; 280:41793–41804.
4.
CiacciarelliM, ZerbinatiC, VioliF, IulianoL: Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem, 2015; 15:822–829.
5.
BalakumarP, NyoYH, RenushiaR, et al.: Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel?. Pharmacol Res, 2014; 87:144–150.
6.
HungCC, YangML, LinMY, et al.: Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease. Kaohsiung J Med Sci, 2014; 30:599–607.
7.
SharmaAK, KhannaD, BalakumarP: Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats. Int J Cardiol, 2014; 172:530–532.
8.
PuriN, MoheyV, SinghM, et al.: Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. Naunyn Schmiedebergs Arch Pharmacol, 2016; 389:361–368.
9.
ElsherbinyNM, Al-GayyarMM, Abd El GalilKH: Nephroprotective role of dipyridamole in diabetic nephropathy: effect on inflammation and apoptosis. Life Sci, 2015; 143:8–17.
10.
DharmshaktuP, TayalV, KalraBS: Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol, 2012; 52:6–17.
11.
ChenG, ParkCK, XieRG, BertaT, NedergaardM, JiRR: Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice. Brain, 2014; 137(Pt 8):2193–2209.
12.
WuA, GreenCR, RupenthalID, Moalem-TaylorG: Role of gap junctions in chronic pain. J Neurosci Res, 2012; 90:337–345.
13.
MoriokaN, SuekamaK, ZhangFF, et al.: Amitriptyline up-regulates connexin43-gap junction in rat cultured cortical astrocytes via activation of the p38 and c-Fos/AP-1 signalling pathway. Br J Pharmacol, 2014; 171:2854–2867.
14.
JeansonT, DuchêneA, RichardD, et al.: Potentiation of amitriptyline anti-hyperalgesic-like action by astroglial connexin 43 inhibition in neuropathic rats. Sci Rep, 2016; 6:38766.
15.
AlmeidaCF, FernandesSA, Ribeiro JuniorAF, Keith OkamotoO, VainzofM: Muscle satellite cells: exploring the basic biology to rule them. Stem Cells Int, 2016; 2016:1078686.
16.
LiuY, LiM, WarburtonRR, HillNS, FanburgBL: The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J, 2007; 21:2725–2734.
17.
SanchezE, GillespieA, TangG, et al.: Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res, 2016; 22:3383–3397.
18.
GuY, MasieroM, BanhamAH: Notch signaling: its roles and therapeutic potential in hematological malignancies. Oncotarget, 2016; 7:29804–29823.
19.
ErdőF, DenesL, de LangeE: Age-associated physiological and pathological changes at the blood-brain barrier: a review. J Cereb Blood Flow Metab, 2017; 37:4–24.
20.
WeissbergI, WoodL, KamintskyL, et al.: Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction. Neurobiol Dis, 2015; 78:115–125.
21.
LapiloverEG, LippmannK, SalarS, et al.: Peri-infarct blood-brain barrier dysfunction facilitates induction of spreading depolarization associated with epileptiform discharges. Neurobiol Dis, 2012; 48:495–506.
22.
DavisSM, LeesKR, AlbersGW, DienerHC, et al.: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke, 2000; 31:347–354.
23.
MorrisGF, BullockR, MarshallSB, MarmarouA, MaasA, MarshallLF: Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J Neurosurg, 1999; 91:737–743.
24.
WallackMK, SivanandhamM, BalchCM, et al.: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg, 1998; 187:69–77; discussion 77–79.
25.
GomellaLG, MastrangeloMJ, McCuePA, MaguireHCJr., MulhollandSG, LattimeEC: Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol, 2001; 166:1291–1295.
26.
SmithCL, DunbarPR, MirzaF, et al.: Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer, 2005; 113:259–266.
27.
FengJ, WangT, ShiW, et al.: Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerg Microbes Infect, 2014; 3:e49.
28.
FengJ, WeitnerM, ShiW, ZhangS, SullivanD, ZhangY: Identification of additional anti-persister activity against Borrelia burgdorferi from an FDA drug library. Antibiotics (Basel), 2015; 4:397–410.
29.
EsmaeiliMA, YadavS, GuptaRK, et al.: Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum Mol Genet, 2016; 25:317–327.
30.
HongM, SongKD, LeeHK, YiS, et al.: Fibrates inhibit the apoptosis of Batten disease lymphoblast cells via autophagy recovery and regulation of mitochondrial membrane potential. In Vitro Cell Dev Biol Anim, 2016; 52:349–355.
31.
WangAM, KuHH, LiangYC, ChenYC, HwuYM, YehTS: The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells. J Cell Biochem, 2009; 106:682–692.
32.
BalgiAD, FonsecaBD, DonohueE, et al.: Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One, 2009; 4:e7124.
33.
JinY, LuZ, DingK, LiJ, et al.: Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res, 2010; 70:2516–2527.
34.
ChenW, ChenM, BarakLS: Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach. Am J Physiol Gastrointest Liver Physiol, 2010; 299:G293–G300.
35.
RenX, DuanL, HeQ, et al.: Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med Chem Lett, 2010; 1:454–459.
36.
PanJX, DingK, WangCY: Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer, 2012; 31:178–184.
37.
WangYC, ChaoTK, ChangCC, YoYT, YuMH, LaiHC: Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells. PLoS One, 2013; 8:e74538.
38.
Bordeira-CarriçoR, PêgoAP, SantosM, OliveiraC: Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med, 2012; 18:667–678.
39.
KeelingKM, BedwellDM: Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med (Berl), 2002; 80:367–376.
40.
FloquetC, DeforgesJ, RoussetJP, BidouL: Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res, 2011; 39:3350–3362.
41.
Baradaran-HeraviA, NiesserJ, BalgiAD, ChoiK, et al.: Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity. Proc Natl Acad Sci USA, 2017; 114:3479–3484.
